olivLaw · US equity research
POMDOCTOR Limited POM
Retail-Miscellaneous Retail · SIC 5900 · Vertical: Retail-Miscellaneous Retail (SIC 5900)
POMDOCTOR is an online medical services platform for chronic diseases in China, combining online consultation and prescription renewal with a pharmaceutical supply chain. For fiscal 2025, net revenues rose 16.7%, while the company still reported an operating loss and sharply higher marketing costs.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, POMDOCTOR Limited (POM) stock was 1.55 USD (+4.73% on the day), with beta 2.69, 52-week range 0.53–109.62 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 53.3
- neutral
- Bollinger (20, 2)
- -0.03 – 2.53
- in the upper half of the band · %B 0.62 · band width 204.3%
- SMA 50 / 200
- 1.02 / 2.90
- mixed trend
- MACD (12, 26, 9)
- 0.21 / 0.19
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +66.7% | −1.1% | +67.8 pp | — |
| 3 months | +121.4% | −0.5% | +121.9 pp | — |
| 6 months | −82.6% | +4.4% | −87.0 pp | — |
| Year to date | −70.8% | +12.3% | −83.1 pp | — |
| 1 year | −98.5% | +13.5% | −112.1 pp | −24.1% |
| 3 years | unavailable | +76.4% | unavailable | −16.4% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | unavailable | unavailable | 57.2 m |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | unavailable | unavailable | -18.7 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -3.14 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | -32.7% |
| Free cash flow | unavailable | unavailable | -21.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.4 m USD
- Financial debt
- 19.3 m USD
- Net debt
- 17.9 m USD
- Equity
- -68.8 m USD
- Total assets
- 15.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.48x
- ROE
- unavailable
- ROA
- -121.7%
- FCF margin
- -37.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2025 | Source (latest year) |
|---|---|---|
| Revenue | 57.2 m | SEC (XBRL)· 14 May 2026verified |
| Cost of revenue | 49.7 m | SEC (XBRL)· 14 May 2026verified |
| Gross profit | 7.5 m | SEC (XBRL)· 14 May 2026verified |
| Research & development | 1.8 m | SEC (XBRL)· 14 May 2026verified |
| Operating income | -17.0 m | SEC (XBRL)· 14 May 2026verified |
| Interest expense | 563.5 k | SEC (XBRL)· 14 May 2026verified |
| Pre-tax income | -18.7 m | SEC (XBRL)· 14 May 2026verified |
| Income tax | 54 | SEC (XBRL)· 14 May 2026verified |
| Net income | -18.7 m | SEC (XBRL)· 14 May 2026verified |
| Diluted EPS | -3.14 | SEC (XBRL)· 14 May 2026verified |
| Weighted average diluted shares | 9.7 m | SEC (XBRL)· 14 May 2026verified |
Balance sheet · USD
| Line | 2025 | Source (latest year) |
|---|---|---|
| Cash | 1.4 m | SEC (XBRL)· 14 May 2026verified |
| Receivables | 2.6 m | SEC (XBRL)· 14 May 2026verified |
| Inventories | 1.2 m | SEC (XBRL)· 14 May 2026verified |
| Current assets | 15.0 m | SEC (XBRL)· 14 May 2026verified |
| Property, plant & equipment, net | 178.3 k | SEC (XBRL)· 14 May 2026verified |
| Total assets | 15.4 m | SEC (XBRL)· 14 May 2026verified |
| Accounts payable | 6.4 m | SEC (XBRL)· 14 May 2026verified |
| Short-term debt | 7.6 m | SEC (XBRL)· 14 May 2026verified |
| Long-term debt | 11.7 m | SEC (XBRL)· 14 May 2026verified |
| Current liabilities | 31.2 m | SEC (XBRL)· 14 May 2026verified |
| Total liabilities | 84.2 m | SEC (XBRL)· 14 May 2026verified |
| Equity | -68.8 m | SEC (XBRL)· 14 May 2026verified |
Cash flow · USD
| Line | 2025 | Source (latest year) |
|---|---|---|
| Operating cash flow | -21.2 m | SEC (XBRL)· 14 May 2026verified |
| Capex | 144.1 k | SEC (XBRL)· 14 May 2026verified |
| Free cash flow | -21.4 m ≈ | SEC (XBRL)· 14 May 2026derived |
| Investing cash flow | -229.9 k | SEC (XBRL)· 14 May 2026verified |
| Financing cash flow | 22.0 m | SEC (XBRL)· 14 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 16.7% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
17% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 16.7% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -32.7% | 18 (vs peers) | 38% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -30.1x | 0 (on a fixed band) | 38% |
| Current ratio · Balance sheet | 0.5x | 0 (on a fixed band) | 25% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial18/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
POMDOCTOR Ltd (POM). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 57.2 m USD in 2025; net margin -32.7%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 16.7% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -32.7%
- Interest coverage: -30.1x
- Current ratio: 0.5x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Retail-Miscellaneous Retail (SIC 5900) · same industry (4-digit SIC) · compared with 12 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| FCFSFirstcash Holdings, Inc. | 8.3 bn | 20.9 | 18.2% | 9.5% | +8.0% | +22% / +73% |
| REALTheRealReal, Inc. | 1.7 bn | — | — | -1.4% | +15.4% | −6% / +500% |
| SVVSavers Value Village, Inc. | 1.5 bn | 63.3 | 5.7% | 1.4% | unavailable | +10% / −33% |
| SPHSuburban Propane Partners LP | 1.1 bn | 7.3 | — | 9.4% | +7.9% | −12% / +0% |
| WINAWinmark Corporation | 987.7 m | 24.8 | — | 45.1% | +5.9% | −32% / −35% |
| TMSTeamshares Inc | 344.7 m | — | -6.7% | — | unavailable | −54% / unavailable |
| PLBYPlayboy, Inc. | 164.1 m | 609.5 | 12.4% | 0.2% | +4.1% | −29% / +161% |
| LIVELIVE VENTURES Inc | 22.9 m | — | -2.8% | -0.6% | −5.9% | −19% / −70% |
| WBUYWebuy Global Ltd | 1.3 m | — | -160.3% | -45.3% | −63.0% | −66% / −100% |
| NEXRNexera Technologies Ltd | 62.0 k | — | -43.2% | -21.8% | +23.0% | −100% / −100% |
| WSHPWeShop Holdings Ltd | — | — | -946.5% | -14,972.7% | −67.3% | −98% / unavailable |
| POMPOMDOCTOR Ltd | — | — | — | -32.7% | unavailable | −99% / unavailable |
| EZPWEzcorp, Inc. | — | 15.1 | 14.7% | 10.0% | +9.7% | +53% / +260% |
1- and 3-year price returns: for POM from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 14 May 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Nov 2026), 6-K (19 Oct 2026), 6-K (09 Oct 2026), 6-K (02 Oct 2026), 6-K (30 Sept 2026).
In brief
POMDOCTOR is an online medical services platform for chronic diseases in China, combining online consultation and prescription renewal with a pharmaceutical supply chain. For fiscal 2025, net revenues rose 16.7% 1, while the company still reported an operating loss and sharply higher marketing costs 1.
SWOT
Strengths
- A network of contracted doctors and a high retention rate for mature doctors point to stable relationships with patients 1.
- Integration between the online platform and the pharmaceutical supply chain creates a complementary business loop 1.
- Focus on chronic diseases creates repeat and predictable demand, which helps retain patients 1.
Weaknesses
Opportunities
- Growth in China's digital healthcare market could create room to expand services 1.
- Extending into other chronic diseases beyond hepatology and andrology could widen the patient base 1.
- Selling clinical data to pharmaceutical companies could become an additional revenue source if the model develops 1.
Threats
- Competitive pressure among Internet hospital platforms may force the company to keep investing in promotion 1.
- The VIE structure through which the company controls its China operations carries legal risks that could affect investors 1.
- Regulation of online drug sales and prescribing could change the conditions under which the company operates 1.
Risks
- VIE structurehigh
The company controls its China operations through a VIE structure, and investors buy ADSs of an offshore holding company rather than shares of the operating entity 1.
- Operating losseshigh
The operating loss widened in 2025, and the source does not indicate when the company might reach profitability 1.
- Marketing costsmedium
Sales and marketing expenses rose sharply in 2025; if these costs stay high, margins could remain under pressure 1.
- Medical and pharmaceutical regulationmedium
The business depends on compliance with rules on online prescribing and drug sales, and regulatory changes could limit the model 1.
- Dependence on doctorslow
Patient relationships rest on contracted doctors, and losing a significant share of them could reduce consultations and prescriptions 1.
Investment thesis
What would need to be true (bull case)
- Internet hospital revenue grew strongly in 2025, suggesting the online model can attract patients and repeat orders 1.
- Doctor retention and patient repurchase rates remain high, indicating durable relationships with users 1.
- China's digital healthcare market could keep growing, and the company already has a platform and a doctor network in place 1.
What would break the thesis
- The company is not profitable and its net loss widened in 2025, which could require additional funding if the trend continues 1.
- Marketing expenses grew much faster than revenue, and gross margin fell in the Internet hospital segment 1.
- The VIE structure and dependence on China's regulatory environment introduce legal and operational risks that are hard to quantify from the source 1.
What to watch
- Trend in operating loss and marketing expensesnext 20-F
- Growth of Internet hospital revenue relative to the pharmaceutical supply chain2026
- 90-day patient repurchase rate and retention of mature doctors2026
- Any changes to the VIE structure or to regulation of online drug salesnext 20-F
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 14 May 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Nov 2026), 6-K (19 Oct 2026), 6-K (09 Oct 2026), 6-K (02 Oct 2026), 6-K (30 Sept 2026).
The business
The company runs two complementary segments: an Internet hospital offering online consultation and prescription renewal for chronic disease patients, and a pharmaceutical supply chain that supplies other pharmaceutical platforms 1. As of December 31, 2025, over 210,000 contracted doctors had issued approximately 3.4 million prescriptions, and transacting patients reached 753,635 1. The ADSs have traded on Nasdaq under the symbol POM since October 2025 1.
The Internet hospital model relies on doctors who take on patients from offline relationships and continue treatment online; the platform only serves follow-up patients who already hold offline prescriptions, and consultations are still text and picture based 1. The retention rate for mature doctors remained high at 98.9% in 2025, and the 90-day patient repurchase rate was 62.1% 1.
The company has built its business around chronic diseases, where patients need repeated follow-up and drug demand is relatively inelastic, which supports long-term doctor and patient relationships 1. Financially, the net loss widened to RMB130.9 million in 2025 1, and the source does not allow firm conclusions about when the business could become profitable.
Segments
Internet hospital
This segment covers online consultation, prescription renewal and online drug sales through the platform. Revenue reached RMB150.7 million in 2025, up 69.3% year on year, mainly due to online pharmacy sales, which rose to RMB149.2 million 1. Gross margin fell to 32.7% in 2025 from 42.7% in 2024 1.
Pharmaceutical supply chain
This segment sells pharmaceutical products at retail and wholesale and provides supply chain management services to other pharmaceutical platforms. Revenue slipped to RMB249.2 million in 2025, down 1.7%, and gross margin remained very thin at 1.2% 1.
Market context
The company ranked sixth in China's Internet hospital market by number of contracted doctors in 2022, according to Frost & Sullivan as cited in the report 1. The exact market share and its trend are not given in the source and should be checked in later filings.
Trends
- Digitalisation of healthcare servicestailwind
Development of hospital information systems and Internet platform technology could extend the infrastructure needed for online chronic disease management 1. This favours platforms already built, such as POMDOCTOR's.
- Post-pandemic health awarenesstailwind
Greater health management awareness after COVID-19 has increased the popularity of online medical services, which the source views as a tailwind for chronic disease management online 1.
- State policies on chronic disease preventionmixed
State policies on chronic disease prevention and treatment could support demand for the company's platform, but the source does not explain how these policies will be applied in practice 1.
- Marketing costs and margin pressureheadwind
Sales and marketing expenses rose to 24.1% of revenues in 2025 from 16.5% in 2024, which points to margin pressure if attracting users stays costly 1.
Competitive position
The source does not name direct competitors and contains no comparative market share data. The company's only stated competitive position is its sixth-place ranking among China's Internet hospital platforms by contracted doctors, according to Frost & Sullivan 1.
The advantages the company claims are the trust carried over from offline doctor relationships and its integration with the pharmaceutical supply chain, which could reduce reliance on third-party suppliers 1. These claims come from the company's own report and have not been independently verified.
- Other Internet hospital platforms in China
The source only mentions the company's ranking among platforms of this type and does not name the others.
- Pharmaceutical platforms buying supply chain services
The company provides these platforms with supply chain management services; the source does not name them.
- Pharmaceutical manufacturers
The company sells these manufacturers' products through its platform, so the relationship may be partnership as much as competition.
- Offline pharmacies and pharmacy chains
The company also operates offline pharmacies, which compete with traditional pharmacy retail.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)19 Oct 2026
- Current report (foreign issuer)09 Oct 2026
- Current report (foreign issuer)02 Oct 2026
- Current report (foreign issuer)30 Sept 2026
- Current report (foreign issuer)29 Sept 2026
- Current report (foreign issuer)24 Sept 2026
- Current report (foreign issuer)10 Sept 2026
- Current report (foreign issuer)04 Sept 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / POMDOCTOR Limited · 14 May 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.